Literature DB >> 16973587

The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9.

Bassel Akache1, Dirk Grimm, Kusum Pandey, Stephen R Yant, Hui Xu, Mark A Kay.   

Abstract

Adeno-associated virus serotype 8 (AAV8) is currently emerging as a powerful gene transfer vector, owing to its capability to efficiently transduce many different tissues in vivo. While this is believed to be in part due to its ability to uncoat more readily than other AAV serotypes such as AAV2, understanding all the processes behind AAV8 transduction is important for its application and optimal use in human gene therapy. Here, we provide the first report of a cellular receptor for AAV8, the 37/67-kDa laminin receptor (LamR). We document binding of LamR to AAV8 capsid proteins and intact virions in vitro and demonstrate its contribution to AAV8 transduction of cultured cells and mouse liver in vivo. We also show that LamR plays a role in transduction by three other closely related serotypes (AAV2, -3, and -9). Sequence and deletion analysis allowed us to map LamR binding to two protein subdomains predicted to be exposed on the AAV capsid exterior. Use of LamR, which is constitutively expressed in many clinically relevant tissues and is overexpressed in numerous cancers, provides a molecular explanation for AAV8's broad tissue tropism. Along with its robust transduction efficiency, our findings support the continued development of AAV8-based vectors for clinical applications in humans, especially for tumor gene therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973587      PMCID: PMC1617255          DOI: 10.1128/JVI.00878-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro.

Authors:  C H Miao; K Ohashi; G A Patijn; L Meuse; X Ye; A R Thompson; M A Kay
Journal:  Mol Ther       Date:  2000-06       Impact factor: 11.454

2.  Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization.

Authors:  Michael A Lochrie; Gwen P Tatsuno; Brian Christie; Jennifer Wellman McDonnell; Shangzhen Zhou; Richard Surosky; Glenn F Pierce; Peter Colosi
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart.

Authors:  Zhong Wang; Tong Zhu; Chunping Qiao; Liqiao Zhou; Bing Wang; Jian Zhang; Chunlian Chen; Juan Li; Xiao Xiao
Journal:  Nat Biotechnol       Date:  2005-02-27       Impact factor: 54.908

4.  Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer.

Authors:  R W Walters; S M Yi; S Keshavjee; K E Brown; M J Welsh; J A Chiorini; J Zabner
Journal:  J Biol Chem       Date:  2001-03-21       Impact factor: 5.157

5.  Attachment of adeno-associated virus type 3H to fibroblast growth factor receptor 1.

Authors:  S D Blackburn; R A Steadman; F B Johnson
Journal:  Arch Virol       Date:  2005-09-30       Impact factor: 2.574

6.  Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection.

Authors:  C E Wobus; B Hügle-Dörr; A Girod; G Petersen; M Hallek; J A Kleinschmidt
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

7.  Directed evolution of adeno-associated virus yields enhanced gene delivery vectors.

Authors:  Narendra Maheshri; James T Koerber; Brian K Kaspar; David V Schaffer
Journal:  Nat Biotechnol       Date:  2006-01-22       Impact factor: 54.908

8.  Adeno-associated virus types 5 and 6 use distinct receptors for cell entry.

Authors:  Michael P Seiler; A Dusty Miller; Joseph Zabner; Christine L Halbert
Journal:  Hum Gene Ther       Date:  2006-01       Impact factor: 5.695

9.  Identification of mouse AAV capsid-specific CD8+ T cell epitopes.

Authors:  Denise E Sabatino; Federico Mingozzi; Daniel J Hui; Haifeng Chen; Peter Colosi; Hildegund C J Ertl; Katherine A High
Journal:  Mol Ther       Date:  2005-11-02       Impact factor: 11.454

10.  Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver.

Authors:  H Nakai; R W Herzog; J N Hagstrom; J Walter; S H Kung; E Y Yang; S J Tai; Y Iwaki; G J Kurtzman; K J Fisher; P Colosi; L B Couto; K A High
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

View more
  177 in total

1.  Directing integrin-linked endocytosis of recombinant AAV enhances productive FAK-dependent transduction.

Authors:  Paul M Kaminsky; Nicholas W Keiser; Ziying Yan; Diana C M Lei-Butters; John F Engelhardt
Journal:  Mol Ther       Date:  2012-01-10       Impact factor: 11.454

Review 2.  Gene therapy in the cornea: 2005--present.

Authors:  Rajiv R Mohan; Jonathan C K Tovey; Ajay Sharma; Ashish Tandon
Journal:  Prog Retin Eye Res       Date:  2011-09-28       Impact factor: 21.198

3.  Structure of AAV-DJ, a retargeted gene therapy vector: cryo-electron microscopy at 4.5 Å resolution.

Authors:  Thomas F Lerch; Jason K O'Donnell; Nancy L Meyer; Qing Xie; Kenneth A Taylor; Scott M Stagg; Michael S Chapman
Journal:  Structure       Date:  2012-06-21       Impact factor: 5.006

4.  Efficient and Targeted Transduction of Nonhuman Primate Liver With Systemically Delivered Optimized AAV3B Vectors.

Authors:  Shaoyong Li; Chen Ling; Li Zhong; Mengxin Li; Qin Su; Ran He; Qiushi Tang; Dale L Greiner; Leonard D Shultz; Michael A Brehm; Terence R Flotte; Christian Mueller; Arun Srivastava; Guangping Gao
Journal:  Mol Ther       Date:  2015-09-25       Impact factor: 11.454

Review 5.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

Review 6.  The AAV vector toolkit: poised at the clinical crossroads.

Authors:  Aravind Asokan; David V Schaffer; R Jude Samulski
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

7.  Recombinant adeno-associated virus vectors in the treatment of rare diseases.

Authors:  Eric Hastie; R Jude Samulski
Journal:  Expert Opin Orphan Drugs       Date:  2015-05-15       Impact factor: 0.694

8.  CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes.

Authors:  Benjamin Steines; David D Dickey; Jamie Bergen; Katherine Jda Excoffon; John R Weinstein; Xiaopeng Li; Ziying Yan; Mahmoud H Abou Alaiwa; Viral S Shah; Drake C Bouzek; Linda S Powers; Nicholas D Gansemer; Lynda S Ostedgaard; John F Engelhardt; David A Stoltz; Michael J Welsh; Patrick L Sinn; David V Schaffer; Joseph Zabner
Journal:  JCI Insight       Date:  2016-09-08

9.  Host and vector-dependent effects on the risk of germline transmission of AAV vectors.

Authors:  Patricia Favaro; Harre D Downey; J Shangzhen Zhou; J Fraser Wright; Bernd Hauck; Federico Mingozzi; Katherine A High; Valder R Arruda
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

10.  Adeno-associated virus-2 and its primary cellular receptor--Cryo-EM structure of a heparin complex.

Authors:  Jason O'Donnell; Kenneth A Taylor; Michael S Chapman
Journal:  Virology       Date:  2009-01-13       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.